The targeted delivery of optimized stem cells directly into injured tissues has been used to maximize efficacy and minimize systemic exposure. Still, despite hundreds of clinical trials evaluating mesenchymal stem cell (MSC) therapy as a treatment, clinical efficacy remains highly variable. Investigators at Case Western Reserve University have developed an optimized combination of cytokines and growth factors applied to MSCs (HXB-319).
Evaxion Biotech A/S has unveiled the technology behind its proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.
Proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to non-receptor tyrosine-protein kinase TYK2-targeting moiety have been reported in a Kymera Therapeutics Inc. patent as potentially useful for the treatment of neurological, inflammatory and endocrine disorders, autoimmune diseases, transplant rejection, graft-vs.-host disease and cancer.
Exo Therapeutics Inc. has announced its lead program directed against TANK-binding kinase 1 (TBK1) for the treatment of autoimmune diseases. The company is now approaching identification of a development candidate for its lead program, an exosite-targeted compound that selectively reprograms the activity of TBK1 in the STING pathway that drives pathogenic signaling in diseases such as systemic lupus erythematosus, Aicardi-Goutières syndrome and others.
China's National Medical Products Administration (NMPA) has given drug clinical trial approval for two new COVID-19 vaccines against the current XBB variants developed by Westvac Biopharma Co. Ltd. and West China Medical Center at Sichuan University.
Dualyx NV has completed a €40 million (US$44 million) series A financing, allowing the company to advance its lead autoimmune program, DT-001, as well as its pipeline of regulatory T-cell (Treg) candidates.
RSS
